WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Osteoporosis Efficacy Criteria v12, Dual energy x-ray absorptiometry (DXA) performed at Time points defined by protocol, Urine for - Hydroxyproline - Pyridinolines - CTX - NTX - Deoxypyridinoline (DPD), T-score assessed only secondarily for 1/3 distal radius, FDA Efficacy Criteria for Osteoporosis additional variables for efficacy consideration Concomitant Medications, - Bone specific alkaline phosphatase(BSAP) - Serum Osteocalcin (OC) - P1NP - P1CP to determine bone formation, Radiographic Report include Type of fracture, Radiographic Test performed at Time points defined by protocol, Biochemical markers of bone turnover tested in Urine, Radiographic Test classified by Quantitative Morphometry, T-score measured in units Standard Deviations (SD), - Glucocorticoids - Calcium - Vitamin D - Bisphosphonate - Estrogens assessed at Baseline, Radiographic Test performed at Time Points defined by symptoms, Concepts are denoted by solid round-edged rectangle, Non-vertebral fracture is confirmed by Radiographic Test, T-score assessed primarily and secondarily for - lumbar vertebrae - total hip - femoral neck, Semi-Quantitative Assessment assesses Vertebral shape, Semi-Quantitative Assessment measured for vertebrae T4 - L5, Biochemical markers of bone turnover tested in Blood, Blood for - Serum c-telopeptides (CTx) - TRAP5b, The proportion of patients with new fracture has outcome assessment Non-vertebral fracture